Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001)

J Neurooncol. 2004 Jan;66(1-2):197-201. doi: 10.1023/b:neon.0000013478.27604.01.


Intratumoral infusion of a recombinant targeted toxin (NBI-3001) consisting of the receptor binding domain of human interleukin 4 (IL-4) and Pseudomonas aeruginosa exotoxin A is an investigational treatment for malignant brain tumors. This 27-year-old male patient presented with a recurrent malignant glioma WHO grade IV after surgery and adjuvant radiation and chemotherapy. The recurrence was treated with intratumoral infusion of NBI-3001 at a dose of 9 microg/ml in 66 ml of infusate. Treatment resulted in long-term survival for 3 years after toxin infusion with a durable tumor response. There were some permanent neurological side effects resulting from toxin infusion. The patient eventually died after a late local recurrence of the known brain tumor. Such clinical evolution of a malignant glioma after a single round of immunotoxin infusion is rather unusual. The late local recurrence may suggest that repeated courses rather than a single infusion of intratumoral toxin are possibly needed for successful long-term tumor control.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Bacterial Toxins / administration & dosage*
  • Bacterial Toxins / adverse effects
  • Brain Neoplasms / diagnosis
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / mortality
  • Exotoxins / administration & dosage*
  • Exotoxins / adverse effects
  • Glioma / diagnosis
  • Glioma / drug therapy*
  • Humans
  • Injections, Intralesional
  • Interleukin-4 / administration & dosage*
  • Interleukin-4 / adverse effects
  • Magnetic Resonance Imaging
  • Male


  • Bacterial Toxins
  • Exotoxins
  • interleukin-4-Pseudomonas exotoxin
  • Interleukin-4